Fidelity Investments
TOVX icon

Fidelity Investments’s Theriva Biologics TOVX Stock Holding History

Fidelity Investments’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,000
Closed -$1.3K – 5584
2025
Q2 		$1.3K Buy
+3,000
New +$2.43K ﹤0.01% 4929
2024
Q3 		– Sell
-20
Closed -$118 – 5728
2024
Q2 		$118 Buy
+20
New +$175 ﹤0.01% 4958
2024
Q1 		– Hold
0
– – – 5306
2023
Q4 		– Sell
-4
Closed -$49 – 5382
2023
Q3 		$54 Buy
+4
New +$61 ﹤0.01% 4922
2023
Q1 		– Hold
0
– -$4 – 5522
2022
Q4 		– Hold
0
– – – 5299
2022
Q3 		– Sell
-4
Closed – – 5406
2022
Q2 		$0 Buy
4
+3
+300% +$172 ﹤0.01% 5482
2022
Q1 		$0 Buy
+1
New +$68 ﹤0.01% 5481
2020
Q4 		– Hold
0
– – – 4279
2020
Q3 		– Sell
-1
Closed -$133 – 3998
2020
Q2 		$0 Buy
+1
New +$95 ﹤0.01% 4164

Other funds holding TOVX

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments's TOVX Position: Q3 2025 in Review

Fidelity Investments sold out of Theriva Biologics (TOVX) in Q3 2025, closing a stake of 3,000 shares — an estimated $1.3K sold.

Fidelity Investments first reported a position in TOVX in Q2 2020 and held it in 6 quarters. The position peaked at $1.3K in Q2 2025. 20 funds tracked by Wall St. Rank hold TOVX as of Q3 2025.

  • Fidelity Investments reported no remaining Theriva Biologics position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 3,000 Theriva Biologics shares in Q3 2025, an estimated $1.3K.
  • Fidelity Investments first reported a position in Theriva Biologics in Q2 2020 and held it in 6 quarters.
  • Fidelity Investments's Theriva Biologics position peaked at $1.3K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.